Syros Pharmaceuticals, Inc. (SYRS)

Market Cap	271.01K
Revenue (ttm)	386.00K
Net Income (ttm)	-97.82M
Shares Out	26.83M
EPS (ttm)	-2.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,143
Average Volume	116,050
Open	0.0100
Previous Close	0.0111
Day's Range	0.0100 - 0.0100
52-Week Range	0.0026 - 6.9280
Beta	1.49
RSI	44.03
Earnings Date	Jul 31, 2025

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 68
• Stock Exchange: OTCMKTS
• Ticker Symbol: SYRS

Financial Performance

In 2023, Syros Pharmaceuticals's revenue was $9.94 million, a decrease of -33.23% compared to the previous year's $14.88 million. Losses were -$164.57 million, 73.9% more than in 2022.